Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

65.28EUR
20 Apr 2018
Change (% chg)

€-0.34 (-0.52%)
Prev Close
€65.62
Open
€65.08
Day's High
€65.74
Day's Low
€65.00
Volume
301,197
Avg. Vol
357,825
52-wk High
€79.05
52-wk Low
€56.55

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €11,689.79
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.34

Financials

  UCB.BR Industry Sector
P/E (TTM): 17.05 30.95 32.74
EPS (TTM): 3.53 -- --
ROI: 8.89 14.84 14.38
ROE: 12.31 16.34 16.07

BRIEF-UCB Acquires Midazolam Nasal Spray From Proximagen

* UCB TO EXPAND EPILEPSY PORTFOLIO WITH STRATEGIC ACQUISITION OF MIDAZOLAM NASAL SPRAY FROM PROXIMAGEN

20 Apr 2018

BRIEF-UCB Acquires Element Genomics

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

05 Apr 2018

BRIEF-UCB: Publication On Cimzia® Shows Psoriatic Arthritis Patients Achieved Treatment Targets

* PUBLICATION ON CIMZIA® SHOWS PSORIATIC ARTHRITIS PATIENTS ACHIEVED TREATMENT TARGETS

03 Apr 2018

BRIEF-UCB Files For Acceptance With China Food And Drug Administration For Cimzia

* UCB ANNOUNCES FILING ACCEPTANCE WITH CHINA FOOD AND DRUG ADMINISTRATION FOR CIMZIA FOR TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

30 Mar 2018

BRIEF-UCB SA U.S. Food And Drug Administration (FDA) Approves Label Change For UCB’S Cimzia®

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LABEL CHANGE FOR UCB’S CIMZIA®

22 Mar 2018

BRIEF-UCB FY Net Sales Up At ‍​4.18 Billion Euros

* FY: REVENUE EUR 4.53‍​ BILLION VERSUS EUR 4.43 BILLION IN REUTERS POLL, NET SALES EUR ‍​4.18 BILLION VERSUS EUR 3.83 BILLION YEAR AGO

22 Feb 2018

BRIEF-UCB To Present Phase 2b Findings For Bimekizumab

* UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018)

16 Feb 2018

BRIEF-UCB Announces That EMA Has Approved Label Change For Cimzia

* LABEL CHANGE MAKING IT FIRST ANTI-TNF FOR POTENTIAL USE IN WOMEN WITH CHRONIC RHEUMATIC DISEASE, DURING PREGNANCY AND BREASTFEEDING Source text : http://bit.ly/2Fe7JUV Further company coverage: (Gdynia Newsroom)

09 Jan 2018

BRIEF-UCB Announces European Medicines Agency Accepts Filing For Evenity

* EUROPEAN MEDICINES AGENCY ACCEPTS FILING FOR EVENITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

08 Jan 2018

BRIEF-UCB Announces Positive Top Line Results Of Phase 2b Bimekizumab Study

* BIMEKIZUMAB DEMONSTRATES IMPRESSIVE JOINT AND SKIN RESPONSES FOR PSORIATIC ARTHRITIS PATIENTS‍​

20 Dec 2017

Earnings vs. Estimates